STAINES-UPON-THAMES, United
Kingdom, March 18, 2019
/PRNewswire/ -- Mallinckrodt plc
(NYSE: MNK), a leading global specialty pharmaceutical company,
today announced that, following an extensive search, Bryan Reasons has been appointed Chief Financial
Officer (CFO), effective immediately. Mr. Reasons will join
Mallinckrodt's Executive Committee, the
company's senior leadership group, and report directly to President
and Chief Executive Officer, Mark
Trudeau. George Kegler, who
has served as interim CFO of Mallinckrodt, will stay on for a transitional
period to ensure a smooth transfer of responsibilities prior to
retiring from the company.
Mr. Reasons brings broad financial leadership experience to
Mallinckrodt, which he gained in
publicly traded pharmaceutical companies known for their success in
research, development and commercialization of branded drugs.
Serving as Senior Vice President and Chief Financial Officer for
six years at Impax Laboratories, Mr. Reasons was instrumental in
the company's 2018 combination with Amneal Pharmaceuticals, Inc.
He began his 25-year finance career in auditing with
PricewaterhouseCoopers, and then progressed through roles of
increasing finance responsibility at E. I. Du Pont De Nemours and
Company, and Cephalon, Inc. Mr. Reasons also serves as an
independent board director and audit committee chair for both
Aclaris Therapeutics, Inc. and Recro Pharma, Inc.
"As Mallinckrodt progresses toward the creation of two
strategically focused public entities with the anticipated
separation of the Specialty Generics and Amitiza®
segment, it is critical that we have a seasoned leader in the Chief
Financial Officer role to help guide us through this
transformation," said Mark
Trudeau, President and Chief Executive Officer.
"We are pleased to bring someone of Bryan's caliber on board, and
believe his background and industry experience will help us meet
these near-term needs. Longer term, we expect he will provide
exceptional leadership as we become wholly focused on our vision to
be an innovation-driven, specialty pharmaceutical growth company
focused on improving outcomes for underserved patients with severe
and critical conditions."
"I'm very excited to be joining Mallinckrodt at this critical time in the company's
evolution," commented Mr. Reasons. "I believe the
company has an exciting future with a sound strategic vision, and
look forward to joining its strong leadership team as we execute on
2019 priorities and, longer term, make the vision a reality."
A graduate of Pennsylvania State
University with a bachelor's degree in accounting and
finance, and of Widener University with
an MBA in accounting, Mr. Reasons is also a Certified Public
Accountant.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The company's Specialty Brands reporting segment's areas
of focus include autoimmune and rare diseases in specialty areas
like neurology, rheumatology, nephrology, pulmonology and
ophthalmology; immunotherapy and neonatal respiratory critical care
therapies; and analgesics. Its Specialty Generics and Amitiza
reporting segment includes specialty generic drugs, active
pharmaceutical ingredients and AMITIZA® (lubiprostone).
To learn more about Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor
Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Media
Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners. © 2019 Mallinckrodt. 03/19
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bryan-reasons-joins-mallinckrodt-as-the-companys-chief-financial-officer-cfo-300813509.html
SOURCE Mallinckrodt plc